<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409032</url>
  </required_header>
  <id_info>
    <org_study_id>NBS-C03-OP</org_study_id>
    <nct_id>NCT00409032</nct_id>
  </id_info>
  <brief_title>A Dose-response Study With Strontium Malonate in Postmenopausal Women</brief_title>
  <official_title>A Dose-response Study With Strontium Malonate in Postmenopausal Women. A 12 Week, Multi National, Double Blind, Randomized, 5 Arms, Parallel Group Placebo Controlled Open Label Active Controlled, Phase II Study With 3 Dose Levels of Strontium Malonate and Protelos Within Post Menopausal Women With a BMDT-score Below -1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osteologix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osteologix</source>
  <brief_summary>
    <textblock>
      The primary objective of the study is to compare dose-response effect of three dose levels of&#xD;
      strontium malonate to placebo on bone resorption quantified by S-CTX-1 following 12 weeks of&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      275 post menopausal women are treated with either 750 mg strontium malonate, 1000 mg&#xD;
      strontium malonate, 2000 mg strontium malonate, 2 g ProtelosÂ® or placebo.&#xD;
&#xD;
      Patients are treated for 12 weeks. A follow up period of 4 weeks is planned for the main&#xD;
      study and a follow up period of 8 weeks is planned for approximately 20% of the patients to&#xD;
      follow post treatment CTX-1 activity.&#xD;
&#xD;
      Apart from S-CTS-1 also response on other bio markers are evaluated as well as BMD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CTX-1</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other bio markers, BMD</measure>
  </secondary_outcome>
  <enrollment>275</enrollment>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Strontium malonate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal women (at least 12 months since last menstruation).&#xD;
&#xD;
          -  BMD (L2-4) T-score between -1 and -3 (at least 20% of the enrolled patients must have&#xD;
             a BMD (L2-4) T-score below -2,5).&#xD;
&#xD;
          -  50 years of age.&#xD;
&#xD;
          -  BMI&lt;30 kg/m2.&#xD;
&#xD;
          -  Total S-Ca level within normal range.&#xD;
&#xD;
          -  Ability to read and understand the information given.&#xD;
&#xD;
          -  The patient has signed an informed consent form according to ICH E6 and local&#xD;
             requirements before any study specific procedure is carried out.&#xD;
&#xD;
          -  Ability to comply with study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of prior fragility fracture (any fracture in wrist, hip or spine appearing&#xD;
             after 40 years of age).&#xD;
&#xD;
          -  History of alcohol or drug abuse.&#xD;
&#xD;
          -  Metabolic bone disease (e.g. pagets disease, bone cancer).&#xD;
&#xD;
          -  History of VTE/DVT.&#xD;
&#xD;
          -  History of kidney transplant.&#xD;
&#xD;
          -  Bilateral oophorectomy.&#xD;
&#xD;
          -  Relevant and treated reduced kidney or liver function.&#xD;
&#xD;
          -  Any malignancy within the last 5 years (except basal cell carcinoma)&#xD;
&#xD;
          -  Any chronic condition likely to affect absorption (e.g. Crohns disease, gluten&#xD;
             enteropathy).&#xD;
&#xD;
          -  Known genetic pre-disposition to VTE/DVT&#xD;
&#xD;
          -  Known hypersensitivity to any of the active substances or excipients.&#xD;
&#xD;
          -  25-OH-vitamin D level below 25 nmol/L&#xD;
&#xD;
          -  Any previous treatment with bisphosphonates, Strontium or fluoride.&#xD;
&#xD;
          -  Treatment during the last 3 months affecting calcium balance or bone metabolism (e.g.&#xD;
             thiazides, corticosteroids, calcitonin, HRT, SERMs, PTH, phosphorus).&#xD;
&#xD;
          -  Treatment during the last week with tetracycline, ciprofloxacin or loop diuretics.&#xD;
&#xD;
          -  PTH out of normal range&#xD;
&#xD;
          -  Use of any drug known to influence the coagulation process (aspirin and other NSAID&#xD;
             allowed)&#xD;
&#xD;
          -  Prothrombin time out of normal range (sec or INR)&#xD;
&#xD;
          -  Inclusion in another clinical study within 30 days before randomization or during this&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Eastell, Professor, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sheffield, Metabolic Bone Centre, Northern General Hospital, Sheffield S5 7AU, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PhaseOneTrials</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medinova Clinic</name>
      <address>
        <city>Northwood</city>
        <state>Middlesex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Wales Clinical Research Centre</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 5GJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Scotland Clinical Research Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G81 2DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Limited Reading Clinical Research Centre</name>
      <address>
        <city>Reading</city>
        <zip>RG2 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Sheffield</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Crosby Clinical Research Centre</name>
      <address>
        <city>Waterloo</city>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Wigan Clinical Research Centre</name>
      <address>
        <city>Wigan</city>
        <zip>WN1 1XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.osteologix.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>December 7, 2006</study_first_submitted>
  <study_first_submitted_qc>December 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2006</study_first_posted>
  <last_update_submitted>October 22, 2009</last_update_submitted>
  <last_update_submitted_qc>October 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2009</last_update_posted>
  <keyword>osteoporosis</keyword>
  <keyword>BMD</keyword>
  <keyword>CTX</keyword>
  <keyword>Post menopausal</keyword>
  <keyword>strontium</keyword>
  <keyword>bone turnover</keyword>
  <keyword>clinical development</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

